Research graph
References from AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics for African American and Black people, 2025
2025 · External reference
CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway
10.1016/j.canlet.2021.03.012 · 2021 · External reference
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
10.2147/ott.s186271 · 2019 · External reference
Safety and activity of programmed cell death 1 versus programmed cell death ligand 1 inhibitors for platinum-resistant urothelial cancer: a meta-analysis of published clinical trials
2021 · External reference
AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
10.1038/s41401-022-01047-6 · 2023 · External reference
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
10.1007/s10120-020-01066-4 · 2020 · External reference
AXL and MET in hepatocellular carcinoma: a systematic literature review
10.1159/000520501 · 2022 · External reference
AXL inhibition improves BRAF-targeted treatment in melanoma
10.1038/s41598-022-09078-z · 2022 · External reference
Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network
10.3389/fcimb.2023.1139998 · 2023 · External reference
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer
10.3389/fimmu.2020.00718 · 2020 · External reference
IL-17 inhibits CXCL9/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors
10.1186/s40425-019-0757-z · 2019 · External reference
10.4049/jimmunol.1800696
10.4049/jimmunol.1800696 · External reference
IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells
10.1084/jem.20070406 · 2007 · External reference
The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance
2025 · External reference
Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer
2022 · External reference
The immune subtypes and landscape of squamous cell carcinoma
10.1158/1078-0432.ccr-18-4085 · 2019 · External reference
Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data
10.3390/cancers12071788 · 2020 · External reference
AXL: shapers of tumor progression and immunosuppressive microenvironments
10.1186/s12943-024-02210-9 · 2025 · External reference
A combined risk score model to assess prognostic value in patients with soft tissue sarcomas
10.3390/cells11244077 · 2022 · External reference
Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment
10.3389/fimmu.2025.1601420 · 2025 · External reference
Axl regulation of NK cell activity creates an immunosuppressive tumor immune microenvironment in head and neck cancer
10.3390/cancers17060994 · 2025 · External reference
Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
10.1158/0008-5472.can-20-0434 · 2021 · External reference
Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
10.1136/jitc-2021-002603 · 2021 · External reference
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
10.1136/jitc-2020-001895 · 2021 · External reference
Incorporation of SKI-G-801, a Novel AXL Inhibitor, with Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor activity and Survival by Enhancing T Cell Immunity
2022 · External reference
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
10.1002/cti2.1364 · 2022 · External reference
Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity
10.1158/0008-5472.can-20-2066 · 2021 · External reference
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
10.1038/s41419-024-06493-0 · 2024 · External reference
Recent discovery and development of AXL inhibitors as antitumor agents
10.1016/j.ejmech.2024.116475 · 2024 · External reference
Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
10.1084/jem.20190354 · 2020 · External reference
AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy
2025 · External reference
10.1073/pnas.2023868118
10.1073/pnas.2023868118 · External reference
IL-17-induced HIF1α drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion
10.1084/jem.20210693 · 2022 · External reference
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
10.1186/s12967-023-04365-3 · 2023 · External reference
Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma
10.1038/s41368-023-00267-8 · 2024 · External reference
Lingual denervation improves the efficacy of Anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling
10.1158/2767-9764.crc-23-0192 · 2024 · External reference
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
10.1038/s41467-025-58179-6 · 2025 · External reference
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.lungcan.2023.107291 · 2023 · External reference
S100A5 attenuates efficiency of anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma
2023 · External reference
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
10.1002/cti2.1364 · ExternalCitation · doi-reference
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
10.1007/s10120-020-01066-4 · ExternalCitation · doi-reference
CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway
10.1016/j.canlet.2021.03.012 · ExternalCitation · doi-reference
Recent discovery and development of AXL inhibitors as antitumor agents
10.1016/j.ejmech.2024.116475 · ExternalCitation · doi-reference
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.lungcan.2023.107291 · ExternalCitation · doi-reference
Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma
10.1038/s41368-023-00267-8 · ExternalCitation · doi-reference
AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
10.1038/s41401-022-01047-6 · ExternalCitation · doi-reference
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
10.1038/s41419-024-06493-0 · ExternalCitation · doi-reference
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
10.1038/s41467-025-58179-6 · ExternalCitation · doi-reference
AXL inhibition improves BRAF-targeted treatment in melanoma
10.1038/s41598-022-09078-z · ExternalCitation · doi-reference
10.1073/pnas.2023868118
10.1073/pnas.2023868118 · ExternalCitation · doi-reference
IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells
10.1084/jem.20070406 · ExternalCitation · doi-reference
Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
10.1084/jem.20190354 · ExternalCitation · doi-reference
IL-17-induced HIF1α drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion
10.1084/jem.20210693 · ExternalCitation · doi-reference
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
10.1136/jitc-2020-001895 · ExternalCitation · doi-reference
Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
10.1136/jitc-2021-002603 · ExternalCitation · doi-reference
Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
10.1158/0008-5472.can-20-0434 · ExternalCitation · doi-reference
Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity
10.1158/0008-5472.can-20-2066 · ExternalCitation · doi-reference
The immune subtypes and landscape of squamous cell carcinoma
10.1158/1078-0432.ccr-18-4085 · ExternalCitation · doi-reference
Lingual denervation improves the efficacy of Anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling
10.1158/2767-9764.crc-23-0192 · ExternalCitation · doi-reference
AXL and MET in hepatocellular carcinoma: a systematic literature review
10.1159/000520501 · ExternalCitation · doi-reference
AXL: shapers of tumor progression and immunosuppressive microenvironments
10.1186/s12943-024-02210-9 · ExternalCitation · doi-reference
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
10.1186/s12967-023-04365-3 · ExternalCitation · doi-reference
IL-17 inhibits CXCL9/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors
10.1186/s40425-019-0757-z · ExternalCitation · doi-reference
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
10.2147/ott.s186271 · ExternalCitation · doi-reference
Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network
10.3389/fcimb.2023.1139998 · ExternalCitation · doi-reference
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer
10.3389/fimmu.2020.00718 · ExternalCitation · doi-reference
Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment
10.3389/fimmu.2025.1601420 · ExternalCitation · doi-reference
Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data
10.3390/cancers12071788 · ExternalCitation · doi-reference
Axl regulation of NK cell activity creates an immunosuppressive tumor immune microenvironment in head and neck cancer
10.3390/cancers17060994 · ExternalCitation · doi-reference
A combined risk score model to assess prognostic value in patients with soft tissue sarcomas
10.3390/cells11244077 · ExternalCitation · doi-reference
10.4049/jimmunol.1800696
10.4049/jimmunol.1800696 · ExternalCitation · doi-reference
